Biotech in Austria: news and updates

News and Trends 29 Sep 2017

Austrian Scientists Turn Human Bone into Surgical Screws

An alternative approach for the repair of broken bones is being developed in Austria, which would overcome major limitations of metal surgical screws. Researchers from TU Graz, Austria, are working with the start-up surgebright to develop surgical screws from donated human bone for foot and jaw surgery. Metal screws are the current standard but these have major limitations […]

September 29, 2017 - 3 minutesmins - By Alex Dale

More News! 18 Sep 2017

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […]

September 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

Apeiron biologics eib efsi funding neuroblastoma

News and Trends 28 Aug 2017

Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer

Apeiron Biologics has been granted financing of €25M from the European Investment Bank (EIB) to support the development of new treatments for cancer. Apeiron Biologics is a biotech based in Vienna focused on developing immuno-oncology treatments designed to make the immune system attack cancer cells. The EIB has decided to support the company’s research of a […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

In Depth 20 Jun 2017

Boosting the Immune System with Vaccines to Fight Cancer: A Review

Immunotherapies have been taking the biotech world by storm. Among these are cancer vaccines, which are directed at solid tumors and aim to boost patients’ immune systems to fight cancer. The cancer vaccine world is broad, with many players. Here’s an overview of some of the current efforts underway by European biotechs. Mastering mRNA One […]

June 20, 2017 - 7 minutesmins - By Diana Kwon

brain organoids tissue engineering austria

News and Trends 2 Jun 2017

Austrian Researchers build an improved Mini-Brain to support Psychiatry

Researchers from Austria and the UK have made new advances in engineering brain-like structures. These lab-grown organoids mimic important functions of the real thing and could help improve understanding of mental illness and test new therapies. The Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna is a pioneer of brain […]

June 2, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […]

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 4 May 2017

Solid First-in-Human Results from Vaccine against Birth Defects

Hookipa has presented positive data from its first Phase I trial testing its vaccine technology against human cytomegalovirus (hCMV) infections. Hookipa, one of the top 10 biotechs we’re closely following this year, is developing a viral vaccine platform that has attracted big investments from both the private and the public sector. The company just announced […]

May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 May 2017

Parent Bacteria Resist Antibiotics Better than their Offspring

According to a new study, a phenomenon known as biased inheritance protects older bacteria from the wrath of antibiotics in low concentrations. Older bacteria in a mixed population of dividing E. coli cells inherit a larger number of drug-expelling membrane proteins and pump out antibiotics better than their younger counterparts in the presence of low […]

May 4, 2017 - 3 minutesmins - By External Contributor

News and Trends 6 Apr 2017

This New Biotech counts with the Largest Antibiotic Resistance Database

Curetis has launched Ares Genetics, a company that will use the biggest antibiotic resistance genetic database to advance the diagnose of infections. Ares Genetics, the new subsidiary of Curetis, will investigate the genetic foundation of antibiotic resistance to develop new approaches for the rapid diagnose of specific resistance in patients with infections, as well as tools to […]

April 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Arsanis Adimab RSV monoclonal antibodies

News and Trends 28 Feb 2017

New Antibodies to Target the Respiratory Syncytial Virus

The two companies Arsanis and Adimab, both specialized in the development of monoclonal antibodies, have partnered up against respiratory syncytial virus (RSV). Their license agreement is backed by the Gates Foundation. The clinical-stage biotech Arsanis is developing monoclonal antibodies (mAbs) for the treatment of serious infectious diseases. The company announced that they have gained the exclusive worldwide […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us